Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
Remi A. Kessler, Maureen A. Mealy, Michael Levy
Current Treatment Options in Neurology (2015) Vol. 18, Iss. 1
Open Access | Times Cited: 138

Showing 1-25 of 138 citing articles:

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Sean J. Pittock, Achim Berthele, Kazuo Fujihara, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 7, pp. 614-625
Open Access | Times Cited: 672
Mechanisms of Autoantibody-Induced Pathology
Ralf J. Ludwig, Karen Vanhoorelbeke, Frank Leypoldt, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 414
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee, Benjamin Greenberg, Jeffrey L. Bennett, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 5, pp. 402-412
Open Access | Times Cited: 367
Neuromyelitis optica
Sven Jarius, Friedemann Paul, Brian G. Weinshenker, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 333
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
Chao Zhang, Meini Zhang, Wei Qiu, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 5, pp. 391-401
Open Access | Times Cited: 228
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
Jan‐Patrick Stellmann, Markus Krumbholz, Tim Friede, et al.
Journal of Neurology Neurosurgery & Psychiatry (2017) Vol. 88, Iss. 8, pp. 639-647
Open Access | Times Cited: 141
Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis
Esther Benamu, José G. Montoya
Current Opinion in Infectious Diseases (2016) Vol. 29, Iss. 4, pp. 319-329
Closed Access | Times Cited: 127
Complementopathies and precision medicine
Eleni Gavriilaki, Robert A. Brodsky
Journal of Clinical Investigation (2020) Vol. 130, Iss. 5, pp. 2152-2163
Open Access | Times Cited: 89
The B cell immunobiology that underlies CNS autoantibody-mediated diseases
Bo Sun, Melanie Ramberger, Kevin C. O’Connor, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 9, pp. 481-492
Open Access | Times Cited: 76
Mortality in neuromyelitis optica is strongly associated with African ancestry
Maureen A. Mealy, Remi A. Kessler, Zoe Rimler, et al.
Neurology Neuroimmunology & Neuroinflammation (2018) Vol. 5, Iss. 4
Open Access | Times Cited: 80
Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder
H. Chen, Wei Qiu, Q. Zhang, et al.
European Journal of Neurology (2016) Vol. 24, Iss. 1, pp. 219-226
Closed Access | Times Cited: 72
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence
Savino Sciascia, Massimo Radin, Jinoos Yazdany, et al.
Rheumatology International (2017) Vol. 37, Iss. 8, pp. 1249-1255
Open Access | Times Cited: 71
Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
Adrian I. Espiritu, Paul Matthew D. Pasco
Multiple Sclerosis and Related Disorders (2019) Vol. 33, pp. 22-32
Closed Access | Times Cited: 59
Satralizumab: First Approval
Young‐A Heo
Drugs (2020) Vol. 80, Iss. 14, pp. 1477-1482
Open Access | Times Cited: 59
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar
Takashi Yamamura, Brian G. Weinshenker, Michael R. Yeaman, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 66, pp. 104025-104025
Open Access | Times Cited: 34
A comprehensive review of the advances in neuromyelitis optica spectrum disorder
Pakeeran Siriratnam, Saif Huda, Helmut Butzkueven, et al.
Autoimmunity Reviews (2023) Vol. 22, Iss. 12, pp. 103465-103465
Open Access | Times Cited: 20
Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database
Ichiro Nakashima, Jin Nakahara, Hideo Yasunaga, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 84, pp. 105502-105502
Open Access | Times Cited: 7
Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions
Maureen A. Mealy, Sarah Mossburg, Su‐Hyun Kim, et al.
Multiple Sclerosis and Related Disorders (2018) Vol. 28, pp. 64-68
Open Access | Times Cited: 56
Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders
Maureen A. Mealy, Su‐Hyun Kim, Felix Schmidt, et al.
Multiple Sclerosis Journal (2017) Vol. 24, Iss. 13, pp. 1737-1742
Open Access | Times Cited: 51
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
James E. Frampton
Drugs (2020) Vol. 80, Iss. 7, pp. 719-727
Open Access | Times Cited: 48
Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders
Itay Lotan, Robert Charlson, Lana Zhovtis Ryerson, et al.
Multiple Sclerosis and Related Disorders (2019) Vol. 39, pp. 101920-101920
Closed Access | Times Cited: 47
Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence
Tetsuya Akaishi, Ichiro Nakashima, Toshiyuki Takahashi, et al.
Neurology Neuroimmunology & Neuroinflammation (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 45
Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)
Xindi Li, De‐Cai Tian, Moli Fan, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 44, pp. 102325-102325
Closed Access | Times Cited: 44
Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy
Xiaoyu Ma, Allan G. Kermode, Xueqiang Hu, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 46, pp. 102522-102522
Closed Access | Times Cited: 43
Neuromyelitis Optica in a Healthy Female After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine
Priscilla Fujikawa, Farhan A Shah, Michalla Braford, et al.
Cureus (2021)
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top